Promentis Pharmaceuticals
Latest round
- Series C
Last raised
- Mar 2017
Total raised
- $17M
Investors
- 5
About Promentis Pharmaceuticals
Promentis Pharmaceuticals, Inc.Founded in 2007, Promentis Pharmaceuticals, Inc. is based in Milwaukee, US. The company focuses on developing treatments for neuropsychiatric disorders. Its founders, David Baker and John Mantsch, have a history in the pharmaceutical domain.Promentis Pharmaceuticals, Inc. focuses on developing innovative therapies aimed at addressing neuropsychiatric disorders, with its core product being SXC-2023. This compound is designed to engage the System x c - target, which plays a crucial role in restoring glutamatergic neurotransmission and addressing oxidative stress imbalances—both significant contributors to impaired cortical function in various CNS disorders. The initial indication for SXC-2023 is trichotillomania, a prevalent condition that affects millions yet lacks FDA-approved treatments.Details regarding the revenue structure of Promentis Pharmaceuticals, Inc. are centered around the development and potential commercialization of its lead compound, SXC-2023. The company engages in business transactions primarily through partnerships with healthcare providers and institutions, potentially involving direct sales to these organizations once products are approved. The proposed structure may include collaborations with clinical research organizations or pharmaceutical companies for joint development, as well as future sales arrangements where healthcare providers obtain the product for their patients.Promentis Pharmaceuticals, Inc. is focused on advancing its lead compound, SXC-2023, with plans for upcoming clinical trials. The company is exploring expansion into European markets, aiming for a presence by 2023.5 mn will be utilized to support the development of SXC-2023 and to facilitate market entry initiatives.
Who invested in Promentis Pharmaceuticals
5 investors across 1 round
See all investors in Promentis Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series C
Mar 30, 2017
Amount
$17M
Investors
Questions about Promentis Pharmaceuticals
Who invested in Promentis Pharmaceuticals?
Promentis Pharmaceuticals has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Promentis Pharmaceuticals raised?
Promentis Pharmaceuticals has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Promentis Pharmaceuticals last raise money?
Promentis Pharmaceuticals's most recent round on record is a Series C, in Mar 2017.
What does Promentis Pharmaceuticals do?
Promentis Pharmaceuticals, Inc.
Where is Promentis Pharmaceuticals headquartered?
Promentis Pharmaceuticals is headquartered in Milwaukee, US.
Which VCs invest in companies like Promentis Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Promentis Pharmaceuticals's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Promentis Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.